| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2002; 41: 253-261
© 2002 British Society for Rheumatology
Original Papers |
Unwillingness of rheumatoid arthritis patients to risk adverse effects
1 Department of Medicine, Yale University, New Haven, CT 06520,
2 VA Connecticut Health Care System, West Haven, CT 06516 and
3 Arthritis Center, Boston University, Boston, MA 02118, USA
Objective. To evaluate patient willingness to accept the risk of adverse effects (AEs) commonly associated with arthritis medications.
Methods. Rheumatoid arthritis patients were asked to rate their willingness to take a medication associated with 17 specific AEs using a visual analogue scale.
Results. We interviewed 100 patients. Eighty-one were currently using one or more disease-modifying anti-rheumatic drugs (DMARDs) and 29 had previously experienced AEs related to DMARDs. Seventy-five stated that they were doing very well or well with respect to their arthritis compared with other people their age. Thirty-five per cent of those interviewed were unwilling to accept the risk of cosmetic changes, 38% were unwilling to accept the risk of temporary discomfort and 45% were unwilling to accept the risk of major toxicity. Patients who had previously experienced AEs were more willing to accept the risk of cosmetic changes (83 vs 58%, P=0.02), temporary discomfort (79 vs 55%, P=0.02) and major toxicity (83 vs 44%, P=0.001) compared with those who had not previously experienced AEs.
Conclusions. Many rheumatoid arthritis patients are very concerned about potential drug toxicity. However, risk aversity appeared to be attenuated by past experience with AEs. Our results suggest that certain patients, especially those with milder disease activity, might be reluctant to accept commonly used arthritis medications if they are fully informed of their potential toxicity.
KEY WORDS: Drug toxicity, Patient attitudes.
Correspondence to: L. Fraenkel, Yale University, Department of Internal Medicine, Section of Rheumatology, P.O. Box 208031, 333 Cedar Street, New Haven, CT 06520-8031, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. M. Seston, D. M. Ashcroft, and C. E. M. Griffiths Balancing the Benefits and Risks of Drug Treatment: A Stated-Preference, Discrete Choice Experiment With Patients With Psoriasis Arch Dermatol, September 1, 2007; 143(9): 1175 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Neame and A. Hammond Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis Rheumatology, June 1, 2005; 44(6): 762 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berry, A. Bradlow, and E. Bersellini Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions Rheumatology, July 1, 2004; 43(7): 901 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fraenkel, S. T. Bogardus Jr, J. Concato, and D. R. Wittink Treatment Options in Knee Osteoarthritis: The Patient's Perspective Arch Intern Med, June 28, 2004; 164(12): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Saravanan and C. A. Kelly Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis Rheumatology, February 1, 2004; 43(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
|
|
A. J. K. Ostor, D. R. O'Gradaigh, and J. R. Jenner Methotrexate for rheumatoid arthritis: what should the patient be told? Rheumatology, December 1, 2003; 42(12): 1576 - 1578. [Full Text] [PDF]
|
|